Cytogenetic and molecular genetic methods for diagnosis and treatment response in chronic granulocytic leukemia

Cancer Genet Cytogenet. 1997 Mar;94(1):59-66. doi: 10.1016/s0165-4608(96)00292-0.

Abstract

Today, laboratory geneticists help clinical hematologists diagnose chronic granulocytic leukemia (CGL) and monitor the response of patients undergoing treatment. The most common genetic tests for CGL include quantitative cytogenetic studies, fluorescence in situ hybridization with probes for BCR and ABL, Southern blot analysis, and reverse transcriptase polymerase chain reaction. No single genetic testing procedure fulfills all the needs of clinicians who care for patients who have CGL. Thus, it has become important to use combinations of testing methods that are both accurate and cost-effective for any given clinical situation in the diagnosis and treatment of patients with CGL.

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Blotting, Southern
  • Bone Marrow Transplantation
  • Chromosomes, Human, Pair 22 / genetics
  • Chromosomes, Human, Pair 9 / genetics
  • Fusion Proteins, bcr-abl / analysis
  • Humans
  • In Situ Hybridization, Fluorescence
  • Interferon-alpha / therapeutic use
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Philadelphia Chromosome
  • Polymerase Chain Reaction
  • Translocation, Genetic

Substances

  • Antineoplastic Agents
  • Interferon-alpha
  • Fusion Proteins, bcr-abl